Drugs / GNG-DE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06834100 | Feb → Dec 2025 overdue | meningococcal infection | NPO Petrovax | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNG-DE | “Group 1 (n = 40) will receive GNG-DE at a dose of 0.5 mL intramuscularly into the deltoid site.” NCT06834100 ↗ |
| Route | Intramuscular | “0.5 mL intramuscularly into the deltoid site” NCT06834100 ↗ |